Back to top
more

Seventy Seven Energy Inc. (SVNT)

(Delayed Data from OTC)

$40.05 USD

40.05
13,017

-0.85 (-2.08%)

Updated Apr 20, 2017 02:01 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[SVNT]

Reports for Purchase

Showing records 1 - 17 ( 17 total )

Industry: Medical - Biomedical and Genetics

Record: 1

08/14/2012

Company Report

Pages: 4

We are dropping coverage of due to realignment of research coverage since analyst departure

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

07/19/2011

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for SVNT

Provider: VALUENGINE, INC

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

05/05/2011

Company Report

Pages: 6

Krystexxa Off to a Very Slow Start

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

04/18/2011

Daily Note

Pages: 19

March Quarter Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

04/11/2011

Company Report

Pages: 18

Battling Gout, Building a Valuable Commercial Asset - Assuming Coverage with an OUTPERFORM Rating

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

04/11/2011

Company Report

Pages: 18

Battling Gout, Building a Valuable Commercial Asset - Assuming Coverage with an OUTPERFORM Rating

Provider: WEDBUSH SECURITIES INC.

Analyst: NALBONE P

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

02/25/2011

Company Report

Pages: 8

Lowering PT to $15 but Maintain Street-High Estimates for Krystexxa; Q4 Earnings Uneventful

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

12/01/2010

Company Report

Pages: 7

Krystexxa Pricing Announced; Raising PT to $17

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

11/05/2010

Company Report

Pages: 6

A Round of Financing Needed to Bridge to Profitability; Pricing of Krystexxa Next Catalyst

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

10/26/2010

Company Report

Pages: 6

Lowering PT to $16 on Failure to Sell

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

09/30/2010

Daily Note

Pages: 22

Biotechnology / Biopharmaceuticals -Preview of Gout Abstracts at the Upcoming ACR

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

09/15/2010

Company Report

Pages: 6

Raising PT to $25 on Potential Takeout in the Near Term.

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

09/10/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences.

Provider: WEDBUSH SECURITIES INC.

Analyst: JAMES S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

09/09/2010

Company Report

Pages: 5

Scenario Analysis of the PDUFA Outcome

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

08/20/2010

Industry Report

Pages: 4

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

08/04/2010

Company Report

Pages: 6

Q2:10 Earnings Uneventful; PDUFA Coming Up in Five Weeks

Provider: WEDBUSH SECURITIES INC.

Analyst: XU Y

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

01/08/2010

Company Report

Pages: 6

Encouraging Update on BLA Resubmission Activities

Provider: WEDBUSH SECURITIES INC.

Analyst: LEE K

Price: 25.00

Research Provided by a Third Party